How Tenvie Therapeutics is testing whether neuroinflammation can become the next obesity treatment frontier
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
XtalPi and ReviR Therapeutics push AI-designed RTX-117 into human trials for rare neurological disorders
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves […]
How United Therapeutics is betting on scaffold-based liver support in high-mortality ALF
United Therapeutics’ miroliverELAP showed positive phase 1 safety results in acute liver failure. Find out what this could mean for future liver support strategies.
PAQ Therapeutics initiates Phase 1 for PT0511 pan-KRAS degrader, raises $77m in Series B
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.
What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?
Lynk Pharmaceuticals and Formation Bio have entered an exclusive licensing and development agreement for LNK01006, a next-generation, central nervous system (CNS)-penetrant TYK2 inhibitor. The deal gives Formation Bio global rights to the asset outside Greater China, with plans to initiate a Phase 1 clinical trial in the United States during the first half of 2026. […]